Abstract:OBJECTIVE:To analyze the clinicopathological features, molecular changes and prognostic factors in angioimmunoblastic T-cell lymphoma (AITL). METHODS:Sixty-one cases AITL diagnosed by Department of Pathology of Peking University Cancer Hospital were collected with their clinical data. Morphologically, they were classified as typeⅠ[lymphoid tissue reactive hyperplasia (LRH) like]; typeⅡ[marginal zone lymphoma(MZL)like] and type Ⅲ [peripheral T-cell lymphoma, not specified (PTCL-NOS) like]. Immunohistochemical staining was used to evaluate the presence of follicular helper T-cell (TFH) phenotype, proliferation of extra germinal center (GC) follicular dendritic cells (FDCs), presence of Hodgkin and Reed-Sternberg (HRS)-like cells and large B transformation. The density of Epstein-Barr virus (EBV) + cells was counted with slides stained by Epstein-Barr virus encoded RNA (EBER) in situ hybridization on high power field (HPF). T-cell receptor / immunoglobulin gene (TCR/IG) clonality and targeted exome sequencing (TES) test were performed when necessary. SPSS 22.0 software was used for statistical analysis. RESULTS:Morphological subtype (%): 11.4% (7/61) cases were classified as type Ⅰ; 50.8% (31/61) as type Ⅱ; 37.8% (23/61) as type Ⅲ. 83.6% (51/61) cases showed classical TFH immunophenotype. With variable extra-GC FDC meshwork proliferation (median 20.0%); 23.0% (14/61) had HRS-like cells; 11.5% (7/61) with large B transformation. 42.6% (26/61) of cases with high counts of EBV. 57.9% (11/19) TCR+/IG-, 26.3% (5/19) TCR+/IG+, 10.5% (2/19) were TCR－/IG－, and 5.3% (1/19) TCR－/IG+. Mutation frequencies by TES were 66.7% (20/30) for RHOA, 23.3% (7/30) for IDH2 mutation, 80.0% (24/30) for TET2 mutation, and 33.3% (10/30) DNMT3A mutation. Integrated analysis divided into four groups: (1) IDH2 and RHOA co-mutation group (7 cases): 6 cases were type Ⅱ, 1 case was type Ⅲ; all with typical TFH phenotype; HRS-like cells and large B transformation were not found; (2) RHOA single mutation group (13 cases): 1 case was type Ⅰ, 6 cases were type Ⅱ, 6 cases were type Ⅲ; 5 cases without typical TFH phenotype; 6 cases had HRS-like cells, and 2 cases with large B transformation. Atypically, 1 case showed TCR－/IG－, 1 case with TCR－/IG+, and 1 case with TCR+/IG+; (3) TET2 and/or DNMT3A mutation alone group (7 cases): 3 cases were type Ⅱ, 4 cases were type Ⅲ, all cases were found with typical TFH phenotype; 2 cases had HRS-like cells, 2 cases with large B transformation, and atypically; (4) non-mutation group (3 cases), all were type Ⅱ, with typical TFH phenotype, with significant extra-GC FDC proliferation, without HRS-like cells and large B transformation. Atypically, 1 case was TCR－/IG－. Univariate analysis confirmed that higher density of EBV positive cell was independent adverse prognostic factors for both overall survival (OS) and progression free survival(PFS), (P=0.017 and P=0.046). CONCLUSION:Pathological diagnoses of ALTL cases with HRS-like cells, large B transformation or type Ⅰ are difficult. Although TCR/IG gene rearrangement test is helpful but still with limitation. TES involving RHOA, IDH2, TET2, DNMT3A can robustly assist in the differential diagnosis of those difficult cases. Higher density of EBV positive cells counts in tumor tissue might be an indicator for poor survival.

[Clinicopathological Analysis of 64 Case of Angioimmunoblastic T-cell Lymphoma].

Clinicopathologic Investigation of Angioimmunoblastic T Cell Lymphoma

[Clinicopathologic, Immunohistochemical and Molecular Analysis in 15 Cases of Angioimmunoblastic T-cell Lymphomas].

[Expressions of CXCL13, CD10 and Bcl-6 in Angioimmunoblastic T-cell Lymphoma and Peripheral T-cell Lymphoma, Not Otherwise Specified].

Analysis of Clinicopathological and Molecular Abnormalities of Angioimmunoblastic T-cell Lymphoma

Angioimmunoblastic T-c ell lymphoma pa tients characteir zed with pure redc ell aplastic anem ia

[Clinicopathological characteristics of angioimmunoblastic T-cell lymphoma with B-cell proliferation or neoplasms]

[Angioimmunoblastic T Cell Lymphoma: Clinical Analysis of 42 Cases].

Angioimmunoblastic T-cell lymphoma:pathological features of tumor cells and the microenvironment

[Angioimmunoblastic T-cell Lymphoma: Histopathological Grading and Prognosis].

Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression

[Angioimmunoblastic T-cell Lymphoma with Large Granular Lymphocytosis].

Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor.

[Retrospective Analysis of 23 Patients with Angioimmunoblastic T Cell Lymphoma].

Angioimmunoblastic T-cell Lymphoma: Treatment Strategies and Prognostic Factors from a Retrospective Multicenter Study in China.

Angioimmunoblastic T-cell Lymphoma with Coexisting Plasma Cell Myeloma: a Case Report and Review of the Literature.

Angioimmunoblastic T-cell Lymphoma with Predominant CD8+ Tumor-Infiltrating T-cells is a Distinct Immune Pattern with an Immunosuppressive Microenvironment.

A new mode for the diagnosis of angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-Cell Lymphoma Diagnosed from Serous Effusion by Integration of Cytologic Features and Ancillary Studies

The Clinicopathological Characteristics of C-MYC Protein in Angioimmunoblastic T-cell Lymphoma

Clinicopathologic Characteristics, Outcomes, and Prognostic Factors of Angioimmunoblastic T-Cell Lymphoma in China